Almuqrin · Genome medicine 2021 · In vitro transcriptomic and proteomic laboratory study · n=?

SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.

Cited 61 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

In vitro laboratory research in cell culture models

PubMed 33722288 · doi:10.1186/s13073-021-00859-1 · record verified 2026-08-30

What was done

Direct RNA sequencing was performed to measure transcript expression from the ChAdOx1 nCoV-19 vaccine vector in replication non-permissive human cell lines (MRC-5 and A549) and a replication-permissive cell line (HEK293). In addition, quantitative proteomics and phosphoproteomics were used to track viral and host protein expression over time in infected A549 and MRC-5 cells.

What was found

The abstract reports no exact numerical values. Expected SARS-CoV-2 spike (S) glycoprotein transcripts dominated expression across all cell lines. Rare spike transcripts with aberrant splicing patterns or altered polyadenylation site usage were detected. Adenovirus vector backbone transcripts were nearly absent in MRC-5 cells, whereas A549 cells expressed a broader repertoire of adenoviral genes at very low levels. Proteomic analysis detected multiple adenovirus proteins in A549 cells compared to a single adenoviral protein in MRC-5 cells alongside the S glycoprotein.

Why it matters

The study provides molecular confirmation that the ChAdOx1 nCoV-19 vaccine functions as intended in human cells, driving high levels of target antigen expression with minimal expression of the replication-deficient adenoviral vector backbone.

Limits

Findings are derived entirely from in vitro human cell culture models (MRC-5, A549, HEK293) and do not directly capture in vivo transcription, biodistribution, or tissue dynamics in human vaccinees. Numerical data for transcript abundances, protein expression levels, and variance were not reported in the abstract. Clinical efficacy, immunogenicity, and safety outcomes were not evaluated.

Cited by